(Reuters) -Eli Lilly plans to launch its blockbuster diabetes and weight-loss drug, Mounjaro, in countries like China, India, ...
Health on MSN7d
Zepbound Is Now Available in Additional Doses at Lower CostsEli Lilly has reduced the prices of certain Zepbound vials and introduced higher-dose options, making the weight-loss drug ...
Eli Lilly partnered up with telehealth providers LifeMD and Teladoc Health to offer its lower cost, single-vial ...
Eli Lilly has launched new 7.5 mg and 10 mg single-dose vials of Zepbound (tirzepatide), priced at $499 per month under the ...
The biotech will commit $150 million to an alliance that hands it significant production capacity for a closely watched ...
Indianapolis-based Eli Lilly and Co. launched LillyDirect a little more than a year ago and has been ramping up efforts to ...
(Nasdaq: LFMD), a leading provider of virtual primary care services, today announced it is integrating with LillyDirect pharmacy provider, Gifthealth, to offer streamlined access of single-dose vials ...
Eli Lilly plans to globally launch its diabetes and weight-loss drug, Mounjaro, in countries including China, India, Brazil, ...
2d
Viking Therapeutics' plans to launch VK2735 with an auto-injector could delay regulatory approval. Click here to read why ...
Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...
However, it is sold as Zepbound for obesity in the U.S. Lilly's drug had a limited launch in China last year, but the company expects a larger launch this year. Danish peer Novo Nordisk launched ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback